Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
773.50-
QQQ
721.290.5%
BTC/USD
79983.501.5904%
DIA
536.520.08%
GLD
410.060.04%
TLT
82.390.39%

Radiopharm Theranostics Ltd

RADXNASDAQ
Trade with Public
Trade with Public
$2.15
-0.01-0.46%
At close: Sep 2, 5:00 PM EST
$2.02
-0.14-6.48%
Pre-Market: 7:03 AM EST
OverviewNewsEventsPrice TargetsFinancialsSentimentCompareStock Report

Radiopharm Theranostics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Radiopharm Theranostics (RADX).

Price Target Range — 5 Quarters

Analyst Consensus — 4 Analysts

4Buy
Consensus RatingBuy# Analysts4Avg. Consensus PT$16Upside to Avg. PT+667.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 4, 2026HC Wainwright & Co.Robert BurnsInitiateBuy$16
Dec 16, 2025B. Riley SecuritiesYuan ZhiPT RaiseBuy$13→$16
More with Benzinga EdgeGet Access

Analyst Ratings News

This HC Wainwright & Co. Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Wall Street analysts began coverage on top names, including a bullish rating on Radiopharm Theranostics. See more analyst ratings.
Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $16

HC Wainwright & Co. analyst Robert Burns initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and announces Price Target of $16.
Benzinga Newsdesk

PRO
B. Riley Securities Reiterates Buy on Radiopharm Theranostics, Raises Price Target to $16

B. Riley Securities analyst Yuan Zhi reiterates Radiopharm Theranostics (NASDAQ:RADX) with a Buy and raises the price target from $13 to $16.
Benzinga Newsdesk

PRO
Brookline Capital Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $18

Brookline Capital analyst Kemp Dolliver initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and announces Price Target of $18.
Benzinga Newsdesk

PRO
Maxim Group Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $12

Maxim Group analyst Michael Okunewitch initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved